AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06154278
Drug: Imdusiran (AB-729)
RxNorm normalized name: Imdusiran
DrugBank: Imdusiran (DB19014)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60mg subcutaneously, every 8 weeks, for a total of 4 doses
Trial: NCT04711850
Drug: Imlifidase
RxNorm normalized name: Imlifidase
DrugBank: Imlifidase (DB15258)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Immunoglobulin G degrading enzyme of Streptococcus pyogenes
Trial: NCT04839575
Drug: Latiglutenase
RxNorm normalized name: LATIGLUTENASE
DrugBank: Latiglutenase (DB06326)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally (daily)
Trial: NCT05551247
Drug: Envafolimab
RxNorm normalized name: Envafolimab
DrugBank: Envafolimab (DB15769)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300mg,sc,d3,Q3W;
Trial: NCT05551247
Drug: recombinant human endostatin (endostatin)
RxNorm normalized name: Pentostatin
DrugBank: Endostatin (DB06423)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 210mg,civ,d1-3,Q3W
Trial: NCT05857930
Drug: OM-85
RxNorm normalized name: OM-85
DrugBank: OM85 (DB16533)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OM-85 capsule (3.5mg) contents will be mixed with adequate quantity of water, fruit juice or milk/formula and orally administered once a day for 6 consecutive months.
Trial: NCT05399576
Drug: Nicorandil
RxNorm normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactically combined intracoronary of Nicorandil and verapamil
Trial: NCT05399576
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intracoronary of 4ml saline
Trial: NCT05267106
Drug: Pemigatinib
RxNorm normalized name: Pemigatinib
DrugBank: Pemigatinib (DB15102)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 13.5mg tablet taken every morning (unless otherwise directed) for 2 weeks and then 1 week off.
Trial: NCT04998201
Drug: ARO-APOC3
RxNorm normalized name: ARO-APOC3
DrugBank: ARO-APOC3 (DB17625)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARO-APOC3 Injection
Trial: NCT03503890
Drug: rovalpituzumab tesirine
RxNorm normalized name: Rovalpituzumab tesirine
DrugBank: Rovalpituzumab tesirine (DB13017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous
Trial: NCT06406829
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The 200ug dexmedetomidine will be diluted into a 50ml syringe and administered with 0.4ug/kg/h intraoperatively and 0.05 μg/kg/h for 48 hours after surgery.
Trial: NCT05783882
Drug: Prolgolimab
RxNorm normalized name: prolgolimab
DrugBank: Prolgolimab (DB16740)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg Q3W
Trial: NCT06430827
Drug: irinotecan hydrochloride liposome injection
RxNorm normalized name: irinotecan hydrochloride liposome Injection
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: rinotecan hydrochloride liposome injection (70mg/m\^2) will be administered by intravenous infusion on day 1 in a 2-week treatment cycle.
Trial: NCT05394831
Drug: JIN-A02
RxNorm normalized name: Yu Jin
DrugBank: Turmeric (DB14276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO, QD
Trial: NCT06610279
Drug: TAK-951
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-951 SC injection
Trial: NCT05470517
Drug: Ceftriaxone
RxNorm normalized name: Ceftriaxone
DrugBank: Ceftriaxone (DB01212)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftriaxone is a sterile, semisynthetic, broad-spectrum cephalosporin antibiotic for intravenous, intramuscular, or intra-peritoneal administration.~Ceftriaxone is a white powder, which is soluble in water. In this study ceftriaxone crystalline powder will be dissolved in 0.9% sodium chloride solution prior to intra-peritoneal instillation.~Antibiotic instillation will be introduced into the RLQ/pelvis after the appendectomy is completed and all intra-peritoneal fluid is aspirated. Ceftriaxone solution will be used depending on availability and pharmacy stock for use at Johns Hopkins All Children's Hospital. The ceftriaxone powder (2g) will be dissolved in 9ml of sterile normal saline, for a total instillation volume of 10ml. This fluid will then be instilled and left to dwell in the area of the peritoneal cavity where the appendix was removed.
Trial: NCT06154447
Drug: VX-828
RxNorm normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspension for Oral Administration
Trial: NCT06154447
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Solution for Oral Administration
Trial: NCT06154447
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Syrup for Oral Administration
Trial: NCT06154447
Drug: Tezacaftor
RxNorm normalized name: Tezacaftor
DrugBank: Tezacaftor (DB11712)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablets for Oral Administration
Trial: NCT06154447
Drug: VX-118
RxNorm normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets for Oral Administration
Trial: NCT05788965
Drug: Semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: glucagon-like peptide 1 (GLP-1) receptor agonist
Trial: NCT04647890
Drug: FT011
RxNorm normalized name: Finerenone
DrugBank: Finerenone (DB16165)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Two x 100mg capsules once daily for 12 weeks
Trial: NCT04647890
Drug: FT011
RxNorm normalized name: Finerenone
DrugBank: Finerenone (DB16165)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Two x 200mg capsules once daily for 12 weeks
Trial: NCT05337033
Drug: MPL-001
RxNorm normalized name: MPL
DrugBank: Monophosphoryl lipid A (DB19290)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBD50 plus is a medical cannabis oil with flavouring agent produced under Good Manufacturing Practice by MediPharm Labs and purchased for this study. Each ml of oil contains 2 mg/ml of delta-9-THC and 50 mg/ml of CBD.~Participants will receive escalating doses from 0.2-0.4 mg/kg/day of CBD to 0.8-1 mg/kg of CBD per day for four months, with dose increases monthly in 0.2mg/kg increments. Participants will following a weekly weaning protocol.
Trial: NCT05567094
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive 0.2 mg/kg dexamethasone, administered as an intravenous bolus within 5 minutes after induction of anesthesia
Trial: NCT06392321
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: comparison between bupivacaine, bupivacaine and dexmedetomidine..
Trial: NCT06016413
Drug: Nab paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: All patients received nab-paclitaxel 260 mg/m2 intravenously on day 1 of each 3-week cycle for 3 cycles.
Trial: NCT06016413
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All patients received carboplatin AUC=5 intravenously on day 1 of each 3-week cycle for 3 cycles.
Trial: NCT06016413
Drug: adelbelimumab
DrugBank: Belimumab (DB08879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: All patients received carboplatin AUC=5 intravenously on day 1 of each 3-week cycle for 3 cycles.
Trial: NCT04675528
Drug: DHP107(Oral paclitaxel)
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: DHP107 200 mg/m\^2 orally twice daily on Day 1, 8, and 15 in every 28 days (On food effect study day, DHP107 200 mg/m\^2 orally once daily on Day 1, 8 of Cycle 1 with fasted or fed condition according to the assigned sequence)
Trial: NCT06702943
Drug: Colistimethate sodium (CMS)
RxNorm normalized name: Colistimethate Sodium
DrugBank: Colistimethate (DB01111)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colistimethate sodium-based regimen (standard therapy for MDR infections) administered both IV and IVT for 14-21 days.
Trial: NCT05287360
Drug: Rivoceranib
RxNorm normalized name: Rivoceranib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivoceranib will be supplied as film-coated tablets for oral administration as 4 different formulations: Formulation 1, 3, and 4 = 250 milligrams; Formulation 2 = 200 milligrams.
Trial: NCT06702670
Drug: Treatment with Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diphenhydramine 50mg IV will be administered within 1 hour of the cervical exam which diagnosed prolonged active phase of labor
Trial: NCT04777591
Drug: Liposomal bupivacaine TAP block
RxNorm normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group will receive Liposomal bupivacaine TAP block (mixed with plain bupivacaine) intraoperatively during free flap breast reconstruction as part of the multimodal pain control.
Trial: NCT04777591
Drug: Bupivacain
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group will receive plain bupivacaine TAP block intraoperatively during free flap breast reconstruction as part of the multimodal pain control.
Trial: NCT05876858
Drug: 18F-FDG
RxNorm normalized name: 18F-FDG
DrugBank: Fludeoxyglucose (18F) (DB09502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each subject will undergo a dynamic 18F-FDG PET/CT scan (this drug is FDA approved) and a dynamic 11C-butanol PET/CT scan (this drug is under an IND) on the EXPLORER total-body PET/CT system. The two scans will be performed on the same day or within a period of up to four weeks depending on subject, imaging agent and scanner availability. Subjects will be asked to complete the HEAL questionnaires before or after their PET/CT scan on each day.
Trial: NCT05337735
Drug: XmAb20717
RxNorm normalized name: Anti-pd1/ctla4 bispecific antibody xmab20717
DrugBank: Vudalimab (DB18833)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by vein (IV)
Trial: NCT05262556
Drug: Nivolumab (3mg/kg)
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenously on Day 1 every three weeks for four cycles (maximum dose 360mg once every 3 weeks), then 240mg maintenance every two weeks for six cycles for a total of six months of treatment.
Trial: NCT05262556
Drug: Ipilimumab (1mg/kg)
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenously on day 1 of each (21-day) cycle for a total of four cycles only.
Trial: NCT04906993
Drug: camrelizumab； famitinib malate
DrugBank: Famitinib (DB11741)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camrelizumab intravenously ; Famitinib Orally
Trial: NCT04906993
Drug: platinum-based chemotherapy
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician's choice chemotherapy
Trial: NCT05768139
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fulvestrant
Trial: NCT05768139
Drug: Ribociclib
RxNorm normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ribociclib
Trial: NCT05768139
Drug: Palbociclib
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib
Trial: NCT06301737
Drug: Lidocaine Hydrochloride
RxNorm normalized name: Lidocaine Hydrochloride
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: the patients were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
Trial: NCT05077683
Drug: Rivaroxaban 2.5 MG [Xarelto]
RxNorm normalized name: rivaroxaban 2.5 MG [Xarelto]
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Experimental group: usual DAPT strategy (aspirin (≤100mg per day), clopidogrel (75mg per day) or ticagrelor (90mg twice daily)) + rivaroxaban 2.5mg twice daily.
Trial: NCT05077683
Drug: DAPT strategy
RxNorm normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: usual DAPT strategy (aspirin (≤100mg per day), clopidogrel (75mg per day) or ticagrelor (90mg twice daily)) +
Trial: NCT04804514
Drug: KH001
RxNorm normalized name: Ketamine hydrochloride
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The study drug is applied to teeth
Trial: NCT00414011
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 drop 4 times daily for 1 week or until complete re-epithelization (usually 3-4 days) after surgery
Trial: NCT00414011
Drug: Gatifloxacin
RxNorm normalized name: Gatifloxacin
DrugBank: Gatifloxacin (DB01044)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 drop 4 times daily for 1 week or until complete re-epithelization (usually 3-4 days) after surgery
Trial: NCT05166239
Drug: Lenvatinib 1
RxNorm normalized name: lenvatinib 10 MG
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 12/8 mg (weight ≥ 60kg / \< 60 kg) of Lenvatinib once daily after HAIC.
Trial: NCT05166239
Drug: PD-1 Inhibitors
RxNorm normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1 inhibitors injection intravenously or percutaneously before 24h of HAIC every 4 week.
Trial: NCT05166239
Drug: Lenvatinib 2
RxNorm normalized name: LENVATINIB 20MG DAILY DOSE PACK,10
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 12/8 mg (weight ≥ 60kg / \< 60 kg) of Lenvatinib once daily.
Trial: NCT06045429
Drug: Chlorhexidine mouthwash
RxNorm normalized name: chlorhexidine Mouthwash
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients in experimental arm will receive usual best medical and nursing care with respect to VAP prevention including recently reviewed local ventilator bundle ; standard microbial surveillance (tracheal aspirate) will be performed twice a week (Monday, Thursday) and always ad hoc according to the clinical situation. This reflects current practice. Daily oral care will be provided using 0,2% chlorhexidine
Trial: NCT05166239
Drug: PD-1 inhibitors 2
RxNorm normalized name: lactate
DrugBank: L-Phospholactate (DB01733)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1 inhibitors injection intravenously or percutaneously every 4 week.
Trial: NCT05709626
Drug: No aspirin (Prasugurel monotherapy)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-month prasugrel monotherapy
Trial: NCT05709626
Drug: 12-month DAPT
RxNorm normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-month dual antiplatelet therapy with prasugrel and aspirin
Trial: NCT06401642
Drug: Zavegepant
RxNorm normalized name: Zavegepant
DrugBank: Zavegepant (DB15688)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg intranasal
Trial: NCT05906511
Drug: Dronabinol 5 MG
RxNorm normalized name: dronabinol 5 MG
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dronabinol 5 mg
Trial: NCT05906511
Drug: Dronabinol 10 MG
RxNorm normalized name: dronabinol 10 MG
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dronabinol 10mg
Trial: NCT05419492
Drug: ETX101
RxNorm normalized name: ETX101
DrugBank: ETX101 (DB18579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ETX101 is a non-replicating, recombinant adeno-associated viral vector serotype 9 (rAAV9) comprising a GABAergic regulatory element (reGABA) and an engineered transcription factor that increases transcription of the SCN1A gene (eTFSCN1A). ETX101 is intended as a one-time intracerebroventricular (ICV) administration.
Trial: NCT06480552
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered intravenously
Trial: NCT06584799
Drug: Diosmin 600
RxNorm normalized name: diosmin 600 MG
DrugBank: Diosmin (DB08995)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venotonic action: the drug reduces venous distensibility, increases venous tone, reduces blood stasis, and enhances the vasoconstrictor effect of epinephrine and norepinephrine. The optimal daily dose of diosmin 600 for obtaining venotonic effect is 600 mg.
Trial: NCT06584799
Drug: Hesperidin+Diosmin combination 1000
RxNorm normalized name: diosmin / hesperidin
DrugBank: Hesperidin (DB04703)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A venotonic agent that also has angioprotective properties. It reduces venous distensibility and blood stasis, reduces capillary permeability and increases their resistance.~Hesperidin+Diosmin combination 1000 dosing regimen is 1000 mg once daily for 2 months
Trial: NCT06319612
Drug: Lidocaine Hydrochloride
RxNorm normalized name: Lidocaine Hydrochloride
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patients were provided with Stellate ganglion block , using 0.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). once a day, 10 days totally.
Trial: NCT05956002
Drug: Estraimod Immediate Release (IR)
RxNorm normalized name: Etrasimod
DrugBank: Etrasimod (DB14766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: an immediate release tablet
Trial: NCT05956002
Drug: Etrasimod Mini Tab in water
RxNorm normalized name: Etrasimod
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: very small tablet mixed in water
Trial: NCT05956002
Drug: Etrasimod Mini Tab in chocolate pudding
RxNorm normalized name: Etrasimod
DrugBank: Etrasimod (DB14766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: very small tablet mixed in chocolate pudding
Trial: NCT05956002
Drug: Etrasimod Mini Tab in yogurt
RxNorm normalized name: Etrasimod
DrugBank: Etrasimod (DB14766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very small tablet mixed in yogurt
Trial: NCT05956002
Drug: Etrasimod Mini Tab in applesauce
RxNorm normalized name: Etrasimod
DrugBank: Apple (DB10501)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very small tablet mixed in applesauce
Trial: NCT04784559
Drug: Plitidepsin
RxNorm normalized name: plitidepsin
DrugBank: Plitidepsin (DB04977)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plitidepsin 2 mg powder is provided as a sterile, preservative-free, and white to off-white lyophilised powder/cake comprising 2 mg plitidepsin and mannitol in a single-dose, 10 mL clear type 1 glass vial.~Solvent for plitidepsin is provided as a sterile, preservative-free, clear, slightly viscous aqueous liquid (4 mL) containing macrogolglycerol ricinoleate and ethanol in a single-dose type 1 clear glass ampoule.~For administration, vial contents are reconstituted by addition of 4 mL of solvent for plitidepsin to obtain a slightly yellowish solution containing 0.5 mg/mL plitidepsin with mannitol, macrogolglycerol ricinoleate and ethanol excipients. The required amount of plitidepsin reconstituted solution is added to bag containing 0.9% sodium chloride or 5% glucose for IV injection and administered as an IV infusion over 60 minutes.
Trial: NCT04784559
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Detailed information about the formulation, posology, packaging and labelling, storage, and manufacturer is provided in the current country-specific product information. The summary of product characteristics (SmPC) and/or leaflet provides detailed product information for investigators in the European Union and/or in other regions.
Trial: NCT04784559
Drug: Remdesivir
RxNorm normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Detailed information about the formulation, posology, packaging and labelling, storage, and manufacturer is provided in the current country-specific product information. The summary of product characteristics (SmPC) and/or leaflet provides detailed product information for investigators in the European Union and/or in other regions.
Trial: NCT04784559
Drug: Favipiravir
RxNorm normalized name: favipiravir
DrugBank: Favipiravir (DB12466)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Detailed information about the formulation, posology, packaging and labelling, storage, and manufacturer is provided in the current country-specific product information. The summary of product characteristics (SmPC) and/or leaflet provides detailed product information for investigators in the European Union and/or in other regions.
Trial: NCT04179500
Drug: Pretomanid
RxNorm normalized name: Pretomanid
DrugBank: Pretomanid (DB05154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pretomanid 200 mg (once daily) for 26 weeks (with meal)
Trial: NCT04179500
Drug: Bedaquiline
RxNorm normalized name: Bedaquiline
DrugBank: Bedaquiline (DB08903)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: bedaquiline 200 mg (once daily) for 8 weeks (with meal), then bedaquiline 100mg (once daily) for 18 weeks (with meal)
Trial: NCT04179500
Drug: moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: moxifloxacin 400 mg (once daily) for 26 weeks (with meal)
Trial: NCT04179500
Drug: pyrazinamide
RxNorm normalized name: Pyrazinamide
DrugBank: Pyrazinamide (DB00339)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pyrazinamide 1500 mg (once daily) for 26 weeks (with meal)